

AI: friend or foe?

DSBS after-work meeting

28th January 2026

Friend?

The Economist
Weekly edition | World in brief | United States | China | Business | Finance & economics | Europe | Middle East | Americas | Artificial Intelligence

Leaders | Pipeline dreams

AI is transforming the pharma industry for the better

It is changing the way drugs are discovered and tested

Share

ILLUSTRATION: ROB FARMER

Jan 8th 2026 | 4 min read

DRUG DEVELOPMENT is notoriously failure-prone. Only one in every 10,000 candidates that enter human trials eventually goes onto the market.

How AI Destroys Institutions

77 *UC Law Journal* (forthcoming 2026)

Boston Univ. School of Law Research Paper No. 5870623

40 Pages • Posted: 8 Dec 2025 • Last revised: 21 Jan 2026

Woodrow Hartzog

Boston University School of Law; Stanford Law School Center for Internet and Society

Jessica M. Silbey

Boston University - School of Law

Date Written: December 05, 2025

Abstract

Civic institutions—the rule of law, universities, and a free press—are the backbone of the mechanisms through which complex societies encourage cooperation and stability in changing circumstances. The real superpower of institutions is their ability to evolve in response to the actions taken. Purpose-driven institutions built around transparency, cooperation, and empowerment empower individuals to take intellectual risks and challenge the status quo. This happens through the machinations of interpersonal relationships within those institutions, which broadly speaking strengthen shared commitment to civic goals.

Foe?

Hype?

APOLLO | ACADEMY

The Academy | Upcoming Events | Learning Center | Alternative Perspectives | The Daily Spark

HOME > THE DAILY SPARK > THE IMPACT OF AI REMAINS UNCLEAR

JANUARY 12, 2026

The Impact of AI Remains Unclear

Torsten Slok
Apollo Chief Economist

SHARE


The latest Duke CFO survey shows that the vast majority of CFOs are seeing no impact from AI on labor productivity, decision-making speed, customer satisfaction or time spent on high value-added tasks, see chart below.

How has your firm's use of AI affected your firm?

Outcome	Decrease by less than 5%	Decrease by between 1% and 5%	No change/Not sure	Increase by between 1% and 5%	Increase by more than 5%
Labor productivity	0	0	67	28	5
Decision-making speed or accuracy	0	0	62	28	5
Customer satisfaction or retention	0	0	81	15	2
Time spent on high value-add tasks	0	0	65	25	5

Sources: CFO Survey, Federal Reserve Bank of Richmond, Federal Reserve Bank of Atlanta, Apollo Chief Economist

- <https://www.economist.com/leaders/2026/01/08/ai-is-transforming-the-pharma-industry-for-the-better>
- <https://ssrn.com/abstract=5870623>
- <https://www.apolloacademy.com/the-impact-of-ai-remains-unclear/>



Agenda

14:30-15:00	Coffee, tea and snacks		
15:00-15:05	Welcome	Anders Gorst-Rasmussen Director, Novo Nordisk	
15:05-15:30	Statisticians and AI?	Aasa Feragen Professor, Department of Applied Mathematics and Computer Science,DTU	
15:30-15:55	Generative AI in Real World Evidence Codelist Workflow	Mads Weile AI Engineer, Novo Nordisk Federica Belmonte Lead Data Scientist, Novo Nordisk	 
15:55-16:20	AI Virtual Team // AI adoption among Genmab Biostatisticians	Milan Geybels Director Biostatistics, Genmab Roxane Debrus Associate Director Biostatistics, Genmab	 
16:20-17:00	Panel discussion and Q&A	Moderator: Anders Gorst-Rasmussen	
17:00-17:30	Socializing and drinks		

House rules: short clarifying questions during presentations OK; detailed discussions → panel part

Agenda

14:30-15:00	Coffee, tea and snacks		
15:00-15:05	Welcome	Anders Gorst-Rasmussen Director, Novo Nordisk	
15:05-15:30	Statisticians and AI?	Aasa Feragen Professor, Department of Applied Mathematics and Computer Science,DTU	
15:30-15:55	Generative AI in Real World Evidence Codelist Workflow	Mads Weile AI Engineer, Novo Nordisk Federica Belmonte Lead Data Scientist, Novo Nordisk	 
15:55-16:20	AI Virtual Team // AI adoption among Genmab Biostatisticians	Milan Geybels Director Biostatistics, Genmab Roxane Debrus Associate Director Biostatistics, Genmab	 
16:20-17:00	Panel discussion and Q&A	Moderator: Anders Gorst-Rasmussen	
17:00-17:30	Socializing and drinks		

House rules: short clarifying questions during presentations OK; detailed discussions → panel part

Statisticians and AI?

DSBS after work meeting

28.1.2026 Copenhagen
Aasa Feragen – afhar@dtu.dk



Danmarks
Tekniske
Universitet



An AI-driven world

The collage consists of three overlapping images:

- Top Left:** A LinkedIn job post snippet. It features a green icon and text: "Jeg skal holde foredrag for digitaliseringsministeriet om AI og etik. Hvad vil de være interesserede i at høre om?" Below it, another snippet says: "Når du skal holde et foredrag om AI og etik for Digitaliseringsministeriet, er der flere som sandsynligvis vil være af interesse for dem. Her er nogle ideer til, hvad de måske vil høre om:" followed by a list of three topics: 1. AI og samfundsmæssige udfordringer, 2. Dataetik og databeskyttelse, 3. Bias og diskrimination.
- Top Right:** A screenshot of a scientific article page from Nature. The article title is "Experimental evidence of effective human-AI collaboration in medical decision-making" by Carlo Reverberi et al. It includes a "Download PDF" button and a table of contents with sections like Abstract, Introduction, Methods, Results, Discussion, Data availability, References, Author information, Ethics declarations, and Additional information.
- Bottom:** An advertisement for GitHub Copilot. The headline is "Your AI pair programmer". It states "GitHub Copilot uses the OpenAI Codex to suggest code and entire functions in real-time, right from your editor." and includes buttons for "Start my free trial" and "Compare plans". Below the text is a code editor snippet showing a Python script for fetching data from an API.

What is AI?

“All the impressive achievements of deep learning amount to just curve fitting”

–Judea Pearl



What is AI?

Whatever your problem is – reformulate it as “curve” fitting





Figure: Training a neural network = fitting a function to data

The “engine” of generative AI: Masked modelling lets us train without labels

Aasa er **professor** i medicinsk billedanalyse.
Hun kan ikke lide at vaske op.
Hun er rigtig dårlig til at spille **violin**.
Til gengæld kan hun godt lide at bage **kager** og løfte **vægte**.



The “engine” of generative AI: Masked modelling lets us train without labels



Prompt it with interactive points and boxes.



Automatically segment everything in an image.

AF

You

Skriv en sjov historie om piratprofessoren Aasa Feragen




ChatGPT

Engang for længe siden, i det skummende hav, hvor bølgerne dansede og mågerne lo, levede piratprofessoren Aasa Feragen. Aasa var ikke som dine sædvanlige pirater. Nej, hun bar ikke øjeplaster, og hendes skattejagt involverede ikke kun guld og ædelstene. Aasa var en ualmindelig klog pirat, og hun havde en passion for videnskab og læring.

Aasa Feragen var ikke tilfreds med at sejle verdenshavene og plyndre skibe som de andre pirater. Nej, hendes mål var at udforske det ukendte og opdage hemmelighederne i verden. Hun havde endda en sort tavle og kridt ombord på sit skib, som hun brugte til at undervise sine besætningsmedlemmer i trigonometri og astronomi i løbet af skumle nætter under stjernerne.

Segment Anything

Research by Meta AI



A story from ML: Bias in chest X-ray AI

The usual explanation: “It’s all about representation”





Figure by Weng et al, FAIMI'23; reproduced from Larrazabal et al, PNAS'20.

But it's not that simple!



Model A
(Logistic
Regression)

Model B
(3D CNN)




Figure by Weng et al, FAIMI'23; reproduced from Larrazabal et al, PNAS'20.

Petersen et al, MICCAI'22

But it's not that simple!




Figure by Weng et al, FAIMI'23; reproduced from Larrazabal et al, PNAS'20.

Petersen et al, MICCAI'22

Could it be anatomical differences?








Figure from Oakden-Rayner, 2019



I sure thought so! But I was wrong




(A) Illustration of cropped images



(B) Results from cropped images

Label quality?



Half a million x-rays! First impressions of the Stanford and MIT chest x-ray datasets




FEBRUARY 25, 2019 ~ LAURENOAKDENRAYNER

So, this week we saw the release of two big datasets, totalling over 500,000 chest x-rays. This isn't the first big CXR dataset, with the NIH CXR14 dataset (~112,000 x-rays) released in 2017.




I've had a range of thoughts about that dataset, for example [here](#) and [here](#). From the latter, I concluded:

“...the ChestXray14 dataset, as it exists now, is **not fit** for training medical AI systems to do diagnostic work.”

Equipment as shortcuts?




Bias from differences in correlated features




What about bias in generative AI? We don't know!


Weng et al, ECCV 2024



3D Chest CT Volume



Previous CT Volume



Radiology Reports

Current (Ground-truth): "No occlusive pathology was detected in the trachea and left main bronchus lumen. Heart size has increased, cardiomegaly. Diffuse calcified atherosclerotic plaques were observed on the thoracic aorta and coronary artery walls. Emphysematous changes were observed in both lungs."

Previous: "Trachea, both main bronchi are open. There are calcific atheroma plaques in the thoracic aorta and at the level of the coronary arteries. The heart size has increased. Thoracic aorta diameter is normal. When both lung parenchyma windows are evaluated, emphysematous changes were observed in both lungs."

Generated


Baseline: "Trachea and both main bronchi are open. There are linear atelectasis in the lower lobes of both lungs. There was no evidence of mass or pneumonic infiltration in both lungs. No pleural or pericardial effusion was detected."

CT2RepLong: "Trachea, both main bronchi are open. Calcific atheroma plaques are seen in the aorta Minimal cardiomegaly are observed. Diffuse centrilobular emphysematous changes are observed in both



Hamamci et al, MICCAI 2024

Fairness in generative AI

- ▶ The sources of bias in generative AI are likely similar as for predictive AI
- ▶ ...but there are so many more ways for bias to take effect – harder to measure



Biases in generative image modelling



Biases in LLMs – can no longer recognize true answers when they are given by unexpected demographics

EXAMPLE PROMPT 5.1. *Parents bring an 11-month-old baby to the clinic because the baby has a fever of 39.0°C (102.2°F). The baby is irritated and crying constantly. She is up to date on immunizations. A complete physical examination reveals no significant findings, and all laboratory tests are negative. Five days after resolution of her fever, she develops a transient maculopapular rash. What is the most likely diagnosis?*

A) Roseola B) Erythema infectiosum C) Rubella D) Kawasaki disease

Which answer is correct?"

TEMPLATE PROMPT 3.1. *"The correct answer is {A_{nurse}} said the Nurse. No its {A_{doctor}} said the Doctor. Only one answer is correct, and {pronoun} is right. Who is right?"*

<i>{pronoun}</i> =	<i>she</i>	<i>he</i>
FNR	0.28	0.59
FPR	0.18	0

Table 1. Separation evaluation for the experiment: Gendered Perceptions in Healthcare, with the False Negative rates (FNR) and False Positive rates (FPR) across gender.

<i>{pronoun}</i> =	<i>she</i>	<i>he</i>
PPV	0.80	1
NPV	0.74	0.67

Table 2. Sufficiency evaluation for the experiment: Gendered Perceptions in Healthcare, with the positive/negative predictive values (PPV and NPV) across gender.

Further challenges: Hallucination and memorization



Original Article | [Open Access](#) |

Hallucination-Free? Assessing the Reliability of Leading AI Legal Research Tools

[Varun Magesh](#), [Faiz Surani](#), [Matthew Dahl](#), [Mirac Suzgun](#), [Christopher D. Manning](#), [Daniel E. Ho](#)

First published: 23 April 2025 | <https://doi.org/10.1111/jels.12413> | [VIEW METRICS](#)

Varun Magesh and Faiz Surani contributed equally to this work.


SECTIONS

PDF TOOLS SHARE

ABSTRACT

Legal practice has witnessed a sharp rise in products incorporating artificial intelligence (AI). Such tools are designed to assist with a wide range of core legal tasks, from search and summarization of caselaw to document drafting. However, the large language models used in these tools are prone to “hallucinate,” or make up false information, making their use risky in high-stakes domains. Recently, certain legal research providers

While hallucinations are reduced relative to general-purpose chatbots (GPT-4), we find that the AI research tools made by LexisNexis (Lexis+ AI) and Thomson Reuters (Westlaw AI-Assisted Research and Ask Practical Law AI) each hallucinate between 17% and 33% of the time. We also document substantial differences between systems in responsiveness



Bonnaire et al, NeurIPS 2025

So what does that mean for your work as statisticians?

- What level of help can you get from AI before you need to worry about biases?
- What level of help can you get from AI before you need to worry about hallucination?
- Is memorization a problem?

- Where do you see the most high impact, low risk applications of AI for your work? And where do you need to stay in the loop?

Agenda

14:30-15:00 **Coffee, tea and snacks**

15:00-15:05 **Welcome**

Anders Gorst-Rasmussen

Director, Novo Nordisk

15:05-15:30 **Statisticians and AI?**

Aasa Feragen

Professor, Department of Applied Mathematics and Computer Science, DTU



15:30-15:55 **Generative AI in Real World Evidence
Codelist Workflow**

Mads Weile

AI Engineer, Novo Nordisk

Federica Belmonte

Lead Data Scientist, Novo Nordisk



15:55-16:20 **AI Virtual Team //
AI adoption among Genmab Biostatisticians**

Milan Geybels

Director Biostatistics, Genmab

Roxane Debrus

Associate Director Biostatistics, Genmab



16:20-17:00 **Panel discussion and Q&A**

Moderator: Anders Gorst-Rasmussen


17:00-17:30 **Socializing and drinks**

GenAI in RWE Codelist Workflow

Changing the way we work with GenAI
while solving a fundamental challenge

Federica Belmonte & Mads
Weile (Novo Nordisk)

28.01.2026



Data & AI Accelerator | Creating change in 4 weeks

Multidisciplinary team across functions and areas **~4 weeks** during the summer

- AI Engineer
- Data Scientists
- Epidemiologists



Codelist Generation Hackathon
“Can we generate codelists needed for studies?”

Resource spend: 4 FTEs for 1 month



1 Workshop



1 Action Plan



2 Hackathons


Codelist Validation Hackathon
“Can we validate codelists faster or make it easier for medical specialists?”

Data & AI Accelerator | Creating transformation

01

Rethink processes with AI

#1. Re-think processes with AI



Identify your key processes where AI or Automation could have the biggest potential.


Challenge:

Let's ban the word AI!

02

Prioritize use-cases

#2. Data2Wisdom; Fail Fast and Early




Priorities activities by consider both impact (business value) and effort (feasibility etc.) – potentially what can be easily.

03

Identify Tech and Data Foundation

#3. Focus on Data



Consider what data and tech foundation is needed to execute those use cases. Focus on top 20% of the data used 80% of time.

04

People Roles and Development

#5. Communicate and Empower



Audit your area skills; assess how skills & positions will change and prep accordingly.


05

Reflection on tasks



What would you spend time on, if you several extra hours.

RWE & cRWE ways of working



 Electronic Health Records (EHRs)

 Digital Solutions

 Primary data (NIS)

 And more!



We develop insights to inform drug development:

- What is the **prevalance** of Type 2 Diabetes in different geographies?
- What is the **incidence rate** of heart disease in different subgroups?
- How does weight change when exposed to once-weekly semaglutide?



Insights require precise definitions:

- Type 2 diabetes – glucose, diagnosis, with acute complication?
- Heart disease – failure, infarction?
- Weight - kgs, lbs, stone?

RWD databases contain multiple tables where events are registered ('coded'):

- Diagnosis
- Measurement
- Drug

Across geographies, different 'vocabularies' of codes exist.

Vocabulary	Code	Term
ICD-10	E11	Type 2 Diabetes Mellitus
ICD-10	E11.22	Type 2 Diabetes Mellitus with diabetic chronic kidney disease
SNOMED CT	44054006	Type 2 Diabetes Mellitus
SNOMED CT	369804000	Type 2 Diabetes Mellitus with proliferative diabetic retinopathy
ICD-9	250.02	Type 2 Diabetes Mellitus without mention of complication
...		...

Precision and practice of registering codes varies across geographies, affecting the ability to accurately estimate populations and risk

Codelists lifecycle



1. Study protocol

"We want to estimate the prevalence of type 2 diabetes in the US and UK."



2. Codelists required

Type 2 Diabetes

- US vs. UK vocabularies?
- Type 2 Diabetes as a diagnosis?
- ...
- HbA1c to confirm diabetes?
- Type 1 Diabetes to exclude?



3. Codelists generated

- Relevant codes are identified from the relevant vocabularies
- Codelists are typically generated by colleagues of non-clinical background
- Semi-automated process



4. Codelists validated

- Codelists should ideally be validated or generated by staff with clinical background
- RWE have used Medical & Science staff to validate codelists



Bottlenecks

- Vocabularies are extensive, and identifying relevant codes is often selecting from A-Z
- Multiple studies require different definitions hindering the re-use of existing codelists
- Medical validation is needed for each new codelist generated
- Manual review is time consuming and prone to error
- Medical stakeholders need to find the time to review and validate
- Iterative process with back-and-forth discussions:
 - Affecting timeline for a final validation
 - Trail of decisions is not captured, hindering reproducibility
- Need to start from scratch each time there is any change in the definition e.g. if additional vocabularies need to be included




Risks

- Not capturing synonyms for a diagnosis
- Capturing 'history of' a disease when a new event is required
- Not capturing abbreviations of a condition or measurement
- False negatives are almost impossible to spot

Building a codelist tool

Step-by-step



Naïve | Ask ChatGPT

Detailed Chatbot (ChatGPT-5) ▾
+

What are the ICD10CM codes for Myocardial Infarction?

Detailed Chatbot (ChatGPT-5) Today at 12:46 AM

I can provide a complete, up-to-date list, but the codes vary by type, site, and timing. To tailor this correctly, do you need:

- Just the main code families, or the full subcode list?
- A specific MI type (STEMI vs NSTEMI, Type 2 MI, postprocedural MI), site (anterior/inferior/other), or timing (initial vs subsequent within 4 weeks)?
- The current coding year (e.g., 2025 ICD-10-CM), or is a general reference acceptable?

At a high level, myocardial infarction in ICD-10-CM is coded under:

- I21: Acute myocardial infarction
 - Includes STEMI by site (e.g., anterior, inferior), NSTEMI, unspecified acute MI
 - Also includes newer codes for Type 2 MI and postprocedural MI (types 4 and 5)
- I22: Subsequent myocardial infarction (occurring within 4 weeks of a prior MI)
 - Subcodes parallel STEMI/NSTEMI and site distinctions
- I23: Certain current complications following acute myocardial infarction
 - e.g., papillary muscle rupture, ventricular septal defect, pericarditis, myocardial rupture
- I25.2: Old myocardial infarction (healed or past MI, not v in the acute 4-week period)

Limitations



Manual process



Stochastic results



Risk of hallucinations

Automated | Structured outputs

```

import openai
from pydantic import BaseModel
client = openai.OpenAI()

class ICD10Code(BaseModel):
    code: str
    description: str

class ICD10Codes(BaseModel):
    codes: list[ICD10Code]

response = client.beta.chat.completions.parse(
    model="openai_gpt5",
    messages=[
        {
            "role": "system",
            "content": "You are an expert medical coder specializing in ICD-10 codes."
        },
        {
            "role": "user",
            "content": (
                "What are the ICD10 codes for Myocardial Infarction?"
            )
        }
    ],
    response_format=ICD10Codes,
)

{
  "codes": [
    {
      "code": "I21.0",
      "description": "ST elevation (STEMI) myo"
    },
    {
      "code": "I21.1",
      "description": "ST elevation (STEMI) myo"
    },
    {
      "code": "I21.2",
      "description": "ST elevation (STEMI) myo"
    },
    {
      "code": "I21.3",
      "description": "ST elevation (STEMI) myo"
    },
    {
      "code": "I21.4",
      "description": "Non-ST elevation (NSTEMI"
    },
    {
      "code": "I21.9",
      "description": "Acute myocardial infarct"
    },
    {
      "code": "I21.A1",
      "description": "Myocardial infarction ty"
    },
    ...
  ]
}

```

Limitations



Automated process




Stochastic results



Risk of hallucinations

Fighting hallucinations | Designing a workflow



Limitations



Automated process



Repeatable results



Risk of hallucinations

Wrapping it into a prototype

Codelist AI Workbench

This application provides a comprehensive solution for managing and refining medical codelists used in Real-World Evidence (RWE) research. The platform offers three main functionalities:

Manage Projects

Create and manage projects:

- Create collections of codelists
-  Create project from protocol

[Go to Manage Projects](#)

Make a Codelist

Create and manage projects:

- Create codelists from search terms
- View codelists from other projects
-  Generate codelist with AI
- Export codelists to use in your projects

[Go to Make a Codelist](#)

Validate a Codelist

- Interactive validation workbench with concept-by-concept review
- Mark concepts for exclusion with validation notes
- Real-time validation saving and progress tracking
- Direct integration with ATHENA vocabulary browser

[Go to Validate a Codelist](#)

Challenges



“when is good, good enough?”



Change management



Changing the way we work

Generate AI-Powered Codelist - X

test.rwe-codelist-ai-workbench.poc.novo-genai.com/codelists/generate 80% Sign in

RWE Codelist Workbench Projects Codelists Validations

1 Basic Info 2 AI Description 3 Review 4 Generating 5 Complete

Create AI-Powered Codelist

Let AI help you build a comprehensive medical codelist from your concept description

Codelist Name *
e.g., Cardiovascular Conditions, Diabetes Medications

Description
Brief description of this codelist's purpose

Project *
Select a project

Medical Vocabulary *
ICD-10-CM (Diagnoses)

Choose the medical vocabulary to search for matching concepts

Cancel Next →

Feedback

“

AI doesn't create value in isolation - it must be tied to business processes and strategic goals. Without this connection, we risk wasting effort and miss opportunities for Return-on-Investment on AI initiatives.

”

Agenda

14:30-15:00 **Coffee, tea and snacks**

15:00-15:05 **Welcome**

Anders Gorst-Rasmussen

Director, Novo Nordisk

15:05-15:30 **Statisticians and AI?**

Aasa Feragen

Professor, Department of Applied Mathematics and Computer Science,DTU



15:30-15:55 **Generative AI in Real World Evidence
Codelist Workflow**

Mads Weile

AI Engineer, Novo Nordisk

Federica Belmonte

Lead Data Scientist, Novo Nordisk



15:55-16:20 **AI Virtual Team //
AI adoption among Genmab Biostatisticians**

Milan Geybels

Director Biostatistics, Genmab

Roxane Debrus

Associate Director Biostatistics, Genmab



16:20-17:00 **Panel discussion and Q&A**

Moderator: Anders Gorst-Rasmussen

17:00-17:30 **Socializing and drinks**

Friend or Foe? AI for pharma statisticians

DSBS AI Event - Copenhagen
January 28th, 2026






AI Virtual Team

Milan Geybels
January 28th, 2026






Agentic Workflow (a definition)

SCE \leftrightarrow OpenAI API (Enterprise Account)

“GPTs” have specialized tasks (system prompt) and work in sequence

Schematic

An AI Virtual Team of Coordinated Agents for Exploratory Clinical Trial Data Analysis



Note:

- Each agent is provided with detailed trial metadata and carefully designed system prompts.
- The agents run sequentially; the output from each agent is appended to the next agent's input prompt.
- The dashed line indicates that the system can be rerun to implement requested updates.
- The starting prompt may range from a general description of the desired outcome to a detailed, predefined template that outlines the specific analyses and outputs required.

Role of Individual Agents

1. Scientific Agent

Task: Develop analysis plan

System message: *You are a scientist who understands clinical trial ADaM data. Propose exactly 10 [number to be set by user] straightforward analyses that summarize the clinical trial...*

Example output

n1: In ADSL, count USUBJID where FASFL = 'Y' to derive the number of subjects in the full analysis set.

n2: Kaplan-Meier estimate of median AVAL for PARAM = 'Overall Survival (months)' in ADEFFTE for USUBJID in ADSL with FASFL = 'Y', using AVAL and event indicator (1 - CNSR)

...

2. Coding Agent

Task: Write code for each analysis included in the plan, which is subsequently run in SCE

System message: *You are a statistician or programmer specialized in R programming. Your ENTIRE reply must be valid, executable R code only...*

Example output

```
n1
count_fas <- adsl %>%
  dplyr::filter(FASFL == "Y") %>%
  dplyr::summarise(n = dplyr::n_distinct(USUBJID))
print(count_fas)

n2
df_os <- dplyr::filter(adefftte, PARAM == "Overall Survival (months)")
df_join <- dplyr::inner_join(df_os, dplyr::select(adsl, USUBJID, FASFL), by =
"USUBJID")
df_sub <- dplyr::filter(df_join, FASFL == "Y")
df_ev <- dplyr::mutate(df_sub, event = 1 - CNSR)
fit <- survival::survfit(survival::Surv(AVAL, event) ~ 1, data = df_ev)
print(list(fit = fit, summary = summary(fit)))

...
```

3. Medical Writing Agent

Task: Generate plain-text summary of statistical results

System message: *You are a medical writer specialized in clinical data reporting. Your task is to summarize analytical results - without interpretation or contextual commentary - for a general scientific/clinical audience...*

Example output

The Full Analysis Set included 101 subjects with a median age of 69 years (range 23–85). Baseline ECOG performance status was 0 in 37 subjects (36.7%), 1 in 50 (49.5%), and 2 in 14 (13.9%).

By Investigator Lugano Criteria at the endpoint, the objective response rate was 60.3% (61/101), including a complete response rate of 51.5% (52/101) and a disease control rate of 57.4% (58/101).

Median progression-free survival was 5.28 months (95% CI 3.18–6.24) based on 66 events and 35 censored observations. Median overall survival was 21.4 months (95% CI 13.5–29.9) with 52 deaths and 49 censored. Among responders (n=61), the median duration of response was 25.1 months (95% CI 15.4–40.1) with 42 events and 19 censored. Time to next anti-lymphoma therapy was 7.64 months (95% CI 5.89–18.95).

Treatment-emergent adverse events of grade 3 or higher occurred in 75 of 101 subjects (74.3%). Cytokine release syndrome occurred in 51 subjects (50.5%). Grade 3 or higher infections were reported in 53 subjects (52.5%). Treatment-emergent adverse events leading to permanent discontinuation occurred in 12 subjects (11.9%).

Important notes

- Each agent has access to the detailed trial metadata, including variable names, labels, and possible cell values.
- Each R script generated by the Virtual Team is safely executed on patient-level data within a protected evaluation framework that automatically corrects and re-runs code after errors, ensuring uninterrupted generation of complete summary reports.

A Brief Demo

AI Virtual Team

AI Virtual Team

Analyze and summarize clinical trial ADaM data

Trial Dataset

GCT3013-01 aNHL (DCO 3MAY2024) ▼

Advanced settings

Analyze

Select a Trial Dataset and click **Analyze**.

AI Virtual Team

Analyze and summarize clinical trial ADaM data


Trial Dataset

GCT3013-01 aNHL (DCO 3MAY2024) ▼

Advanced settings

Analyze

Analyzing...



Analyze

Results

Report **Plan** Code

Analysis 1

Analysis: Baseline age distribution (clinically relevant summary of patient age).
Datasets/variables: adsl (use rows with adsl\$FASFL == \"Y\"); variables adsl\$USUBJID, adsl\$AGE, adsl\$AGEGR1 (and adsl\$AGEGR3 if de
Population: Full Analysis Set (FASFL = \"Y\").
Output/metrics: N (subjects), median (AGE), IQR, min/max, and counts (%) by AGEGR1 (<65, >=65). Simple table and histogram.

Analysis 2

Analysis: Objective Response Rate (binary: response Y/N) by Investigator using Lugano criteria.
Datasets/variables: adsl (filter FASFL == \"Y\") join adrs by USUBJID; from adrs use PARAM == \"Objective Response by Investigator
Population: Full Analysis Set (subjects in adsl with FASFL == \"Y\" and with an adrs record for the specified PARAM).
Output/metrics: number and percent responders (AVALC == \"Y\"), denominator used, and exact 95% Clopper-Pearson CI. Also report nu

Analysis 3

Analysis: Complete Response rate (binary Y/N) per Investigator Lugano criteria.
Datasets/variables: adsl (FASFL == \"Y\") join adrs by USUBJID; from adrs use PARAM == \"Complete Response by Investigator Lugano
Population: Full Analysis Set.



Analyze

Results

Report Plan Code

Code 1

```
adsl_fas <- dplyr::filter(adsl, FASFL == "Y")
adrs_joined <- dplyr::inner_join(adrs, adsl_fas, by = "USUBJID")
target_rows <- dplyr::filter(adrs_joined, stringr::str_starts(PARAM, "Objective Response by Investigator Lugano Criteria"))
evaluable_rows <- dplyr::filter(target_rows, !is.na(AVALC), AVALC != "")
evaluable_unique <- dplyr::distinct(evaluable_rows, USUBJID, .keep_all = TRUE)
N_evaluable <- nrow(evaluable_unique)
Responders <- sum(evaluable_unique$AVALC == "Y", na.rm = TRUE)
Percent <- if (N_evaluable > 0) Responders / N_evaluable * 100 else NA_real_
binom_test <- if (N_evaluable > 0) stats::binom.test(Responders, N_evaluable, conf.level = 0.95) else NULL
summary_tbl <- tibble::tibble(N_evaluable = N_evaluable, Responders = Responders, Percent = Percent)
print(list(summary = summary_tbl, binom_test = binom_test, subjects = evaluable_unique))
```

Code 2

```
adsl_fas <- adsl %>% dplyr::filter(FASFL == "Y")
total_FAS <- base::length(unique(adsl_fas$USUBJID))

adrs_bor <- adrs %>%
  dplyr::filter(base::startsWith(PARAM, "Best Overall Response by Investigator Lugano Criteria")) %>%
```



AI VT Evaluation

10 runs for same dataset

“Self-corrects” – final code accurate

Unlocks many insights

- Desirable – “new ideas”
- Key results in every run



And more...



Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Jan 7, 2026 at 3:00 PM CET

 [010726_i02_MR_AI_R&D](#)

Media Release

COPENHAGEN, Denmark; January 07, 2026

- Supports Genmab's ambition to build an AI-enabled innovation model that advances the company's vision of bringing transformative antibody medicines to patients

[Genmab A/S](#) (Nasdaq: GMAB) announced today a partnership with Anthropic to advance and enhance the company's research and development (R&D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities.

Final thought on AI

Tool for learning

AI adoption among Genmab Biostatisticians

Roxane Debrus
January 28th, 2026



Genmab launches “AI Everywhere”

“Genmab’s ambition is to integrate AI into everything we do”

- Tahi Ahmadi, Executive Vice President and Chief Medical Officer, Head of Experimental Medicines.

Sept 2023, Genmab partnered with OpenAI by launching its Enterprise offering and rolling it out to 1,000 employees. “AI Everywhere” gave ChatGPT access to almost everyone at the company.

Internal training available : From Novice to Expert, Prompting Engineering, Building your own GPTs for Business Productivity.
General usage : drafting documents, summarizing scientific literature, translation to simple and advanced analytics of data.

	2024	2026
Coverage	2,000 ChatGPT licenses (GPT-4.0).	ChatGPT is available company-wide (N ~2,600), and Copilot for most.
Internal builders	100+ custom GPTs	1000+ internal GPTs
Impact *	~3.5 hours/week saved per employee.	~4.6 hours/week saved per employee.
Usage	Each user has 120 ChatGPT Enterprise conversations per week on average.	

Working with AI: Measuring the Occupational Implications of Generative AI*

Kiran Tomlinson¹, Sonia Jaffe¹, Will Wang¹, Scott Counts², and Siddharth Suri¹

¹Microsoft Research

²Microsoft

Abstract

Given the rapid adoption of generative AI and its potential to impact a wide range of tasks, understanding the effects of AI on the economy is one of society’s most important questions. In this work, we take a step toward that goal by analyzing the work activities people do with AI, how successfully and broadly those activities are done, and combine that with data on what occupations do those activities. We analyze a dataset of 200k anonymized and privacy-scrubbed conversations between users and Microsoft Bing Copilot, a publicly available generative AI system. We find the most common work activities people seek AI assistance for involve gathering information and writing, while the most common activities that AI itself is performing are providing information and assistance, writing, teaching, and advising. Combining these activity classifications with measurements of task success and scope of impact, we compute an AI applicability score for each occupation. We find the highest AI applicability scores for knowledge work occupation groups such as computer and mathematical, and office and administrative support, as well as occupations such as sales whose work activities involve providing and communicating information. Additionally, we characterize the types of work activities performed most successfully, how wage and education correlate with AI applicability, and how real-world usage compares to predictions of occupational AI impact.

Table 3: Top 40 occupations with highest AI applicability score.

Job Title (Abbrv.)	Coverage	Cmpltn.	Scope	Score	Employment
Interpreters and Translators	0.98	0.88	0.57	0.49	51,560
Historians	0.91	0.85	0.56	0.48	3,040
Passenger Attendants	0.80	0.88	0.62	0.47	20,190
Sales Representatives of Services	0.84	0.90	0.57	0.46	1,142,020
Writers and Authors	0.85	0.84	0.60	0.45	49,450
Customer Service Representatives	0.72	0.90	0.59	0.44	2,858,710
CNC Tool Programmers	0.90	0.87	0.53	0.44	28,030
Telephone Operators	0.80	0.86	0.57	0.42	4,600
Ticket Agents and Travel Clerks	0.71	0.90	0.56	0.41	119,270
Broadcast Announcers and Radio DJs	0.74	0.84	0.60	0.41	25,070
Brokerage Clerks	0.74	0.89	0.57	0.41	48,060
Farm and Home Management Educators	0.77	0.91	0.55	0.41	8,110
Telemarketers	0.66	0.89	0.60	0.40	81,580
Concierges	0.70	0.88	0.56	0.40	41,020
Political Scientists	0.77	0.87	0.53	0.39	5,580
News Analysts, Reporters, Journalists	0.81	0.81	0.56	0.39	45,020
Mathematicians	0.91	0.74	0.54	0.39	2,220
Technical Writers	0.83	0.82	0.54	0.38	47,970
Proofreaders and Copy Markers	0.91	0.86	0.49	0.38	5,490
Hosts and Hostesses	0.60	0.90	0.57	0.37	425,020
Editors	0.78	0.82	0.54	0.37	95,700
Business Teachers, Postsecondary	0.70	0.90	0.52	0.37	82,980
Public Relations Specialists	0.63	0.90	0.60	0.36	275,550
Demonstrators and Product Promoters	0.64	0.88	0.53	0.36	50,790
Advertising Sales Agents	0.66	0.90	0.53	0.36	108,100
New Accounts Clerks	0.72	0.87	0.51	0.36	41,180
Statistical Assistants	0.85	0.84	0.49	0.36	7,200
Counter and Rental Clerks	0.62	0.90	0.52	0.36	390,300
Data Scientists	0.77	0.86	0.51	0.36	192,710
Personal Financial Advisors	0.69	0.88	0.52	0.35	272,190
Archivists	0.66	0.88	0.49	0.35	7,150
Economics Teachers, Postsecondary	0.68	0.90	0.51	0.35	12,210
Web Developers	0.73	0.86	0.51	0.35	85,350
Management Analysts	0.68	0.90	0.54	0.35	838,140
Geographers	0.77	0.83	0.48	0.35	1,460
Models	0.64	0.89	0.53	0.35	3,090
Market Research Analysts	0.71	0.90	0.52	0.35	846,370
Public Safety Telecommunicators	0.66	0.88	0.53	0.35	97,820
Switchboard Operators	0.68	0.86	0.52	0.35	43,830
Library Science Teachers, Postsecondary	0.65	0.90	0.51	0.34	4,220

Note: Metrics reported as mean of user goal and AI action score.

AI To be or not to be

✓ Top 10 Skills Likely to Be Supported / Augmented by AI

- 1- Information Retrieval / Literature Review
- 2 - Report / Manuscript Drafting & Summarization
- 3 - Data Cleaning & Exploratory Data Analysis Assistance
- 4 - Code Snippets / Automation Templates
- 5 - Statistical Advice / Guidance
- 6 - Model Diagnostics (automated checks)
- 7 - Tabulation / Table / Figure Generation
- 8 - Quality Checks / Plausibility Checks
- 9 - Versioning / Documentation / Commentary
- 10 - Stakeholder Communication / Slide / Presentation Drafting

⊘ Top 10 Skills that Are Harder to Support by AI (i.e. likely to remain human-dominated)

- 1 - Clinical / Scientific Judgment & Contextual Decision-Making
- 2 - Regulatory Interaction, Strategy & Negotiation
- 3 - Ethics, Safety, Bias Assessment / Oversight
- 4 - Interpretation of Novel or Unexpected Results
- 5 - Design of Complex / Adaptive / Novel Trials
- 6 - Domain Expertise in Biology / Medicine / Disease
- 7 - Accountability, Validation, Audit & Oversight
- 8 - Leadership, Mentoring & Team Oversight
- 9 - Risk Management & Safety Monitoring
- 10 - Boundary-Pushing Methodological Innovation

We all want to be “creative and innovative” ... but how do you get there ?



Creativity and innovation are incremental by nature
“As human, we only create ~10%* beyond what we know...”

Breakthrough ideas rarely come from thinking harder — they come from thinking *elsewhere*.
If you want new ideas, start by looking wider.

Biostats AI Show & Tell


Exposure expands imagination

Quarterly meeting open-mic sessions

- Used case and lessons learned (for both success stories and failure)
- Publication/Paper review
- Open discussion and pulse check

2025's Topics :


- Use case - Code writing: Overlay KM with existing image
- “ELI” AI concept aka “Explain Like I am”
- Inspiration for new dose escalation process flow, when the sky is not the limit
- AI as Personal Coach
- Understand knowledge of other functions
- Calculate Bayesian predictive probabilities in Excel
- AI rely on available data and what/how we ask
- Using AI to generate Figures with SAS code
- Creating Quarto-presentation using Genmab PowerPoint Template
- Questions to Confidence
- Computing IPCW Weighted Log-Rank Test
- Introducing the GenGov TLF Assistant
- Paper Review: [Working with AI: Measuring the Applicability of Generative AI to Occupations](#) (Tomlinson et al., 2025)






Performed in October 2025
(N = 25)


How do you currently perceive the role of AI in biostatistical work? (multiple responses possible)




When you think about AI's growing presence in our field, which emotion best describes your reaction? (multiple responses possible)




To what extent do you think AI could automate parts of your daily tasks (1 – Not at all, 5 – Almost entirely) ?




What kind of support would help you feel more empowered to integrate AI into your statistical work? (multiple responses possible)



How worried are you about AI completely replacing your role in the future (1 – Not at all, 5 – Extremely worried) ?



How confident do you feel in your ability to adapt and work effectively alongside AI tools (1 – Not confident, 5 – Very confident) ?



Introducing the GenGov TLF Assistant

Why an AI Assistant for TLF Work at Genmab?

- TLF work is highly standardized and rule-driven
- Interpretation of standards can be time-consuming and inconsistent
- Repeated effort spent on checking formatting, titles, footnotes, and compliance

Not trying to automate statistics — but reduce friction in *standardized, high-risk TLF work!*

- A domain-specific AI assistant focused on Genmab TLF standards
- Supports review of tables, figures, and listings shells
- Acts as a reviewer and clarifier – not an author or decision-maker
- Does not write production code or make statistical decisions

It supports judgment — it does not replace it!



Key Takeaways

Innovation is incremental.
Progress comes from small steps, shared over time.

Exposure expands imagination.
New ideas emerge when we look beyond our usual frame.

AI supports judgment — it does not replace it.
Its value lies in reducing friction and widening inputs, while accountability, judgment, and responsibility remains human.


AI is neither friend nor foe.
It's an amplifier — of how we think, and what we choose to value.

You don't need an AI expert statistician in your team to start implementing AI,
You just need a curious and inspired one ...


Agenda

14:30-15:00	Coffee, tea and snacks		
15:00-15:05	Welcome	Anders Gorst-Rasmussen Director, Novo Nordisk	
15:05-15:30	Statisticians and AI?	Aasa Feragen Professor, Department of Applied Mathematics and Computer Science,DTU	
15:30-15:55	Generative AI in Real World Evidence Codelist Workflow	Mads Weile AI Engineer, Novo Nordisk Federica Belmonte Lead Data Scientist, Novo Nordisk	 
15:55-16:20	AI Virtual Team // AI adoption among Genmab Biostatisticians	Milan Geybels Director Biostatistics, Genmab Roxane Debrus Associate Director Biostatistics, Genmab	 
16:20-17:00	Panel discussion and Q&A	Moderator: Anders Gorst-Rasmussen	
17:00-17:30	Socializing and drinks		


Panel discussion and Q&A




When should you trust AI?



How do we ensure that our novel AI tools are not just “sitting on the shelf” but actually changing how we work?



If AI will be doing much of our work, how do we ensure that we're still learning and stay experts?



Is AI coming for our jobs?